View in EDS

Promethium-149 (149Pm) as a potential theranostic radioisotope: a feasibility study of 149Pm production at the Bandung TRIGA research reactor.

Saved in:
Bibliographic Details
Title: Promethium-149 (149Pm) as a potential theranostic radioisotope: a feasibility study of 149Pm production at the Bandung TRIGA research reactor.
Authors: Aziz, Azmairit1 (AUTHOR), Umar, Efrizon2 (AUTHOR), Basuki, Prasetyo3 (AUTHOR), Ratnawati, Neni3 (AUTHOR), Fathadina, Almira4 (AUTHOR), Permana, Sidik5 (AUTHOR), Ramadhan, Anwar Ilmar6 (AUTHOR) anwar.ilmar@umj.ac.id
Source: Journal of Radioanalytical & Nuclear Chemistry. May2026, Vol. 335 Issue 5, p3781-3796. 16p.
Subject Terms: *Radioisotopes, *Research reactors, *Nuclear medicine, *Nuclear activation analysis, *Radiopharmaceuticals, *Cancer treatment
Geographic Terms: Bandung (Indonesia)
Abstract: Promethium-149 (149Pm) is a no carrier added radiolanthanide that emits moderate-energy beta particles and has high potential as a novel theranostic radioisotope for nuclear medicine applications. This study describes the production of the 149Pm radioisotope from enriched neodymium oxide (Nd2O3) targets at the Bandung TRIGA research reactor and its supporting facilities, including theoretical calculations using computer codes, target preparation, neutron activation, separation of 149Pm radionuclide from Nd/Pm matrix, purification, and physicochemical characterization. The obtained 149Pm was in the form of a 149PmCl3 solution, which remained stable at room temperature for up to 8 days after preparation with high radiochemical and radionuclide purities, thereby fulfilling the requirements for use as a precursor in the preparation of various targeted radiopharmaceuticals for cancer therapy. [ABSTRACT FROM AUTHOR]
Database: Energy & Power Source
Description
Abstract:Promethium-149 (149Pm) is a no carrier added radiolanthanide that emits moderate-energy beta particles and has high potential as a novel theranostic radioisotope for nuclear medicine applications. This study describes the production of the 149Pm radioisotope from enriched neodymium oxide (Nd2O3) targets at the Bandung TRIGA research reactor and its supporting facilities, including theoretical calculations using computer codes, target preparation, neutron activation, separation of 149Pm radionuclide from Nd/Pm matrix, purification, and physicochemical characterization. The obtained 149Pm was in the form of a 149PmCl3 solution, which remained stable at room temperature for up to 8 days after preparation with high radiochemical and radionuclide purities, thereby fulfilling the requirements for use as a precursor in the preparation of various targeted radiopharmaceuticals for cancer therapy. [ABSTRACT FROM AUTHOR]
ISSN:02365731
DOI:10.1007/s10967-026-10894-0